AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) was the target of a significant decline in short interest during the month of October. As of October 15th, there was short interest totalling 348,900 shares, a decline of 14.2% from the September 15th total of 406,500 shares. Based on an average daily trading volume, of 148,100 shares, the short-interest ratio is currently 2.4 days. Currently, 2.1% of the company’s stock are short sold.
A number of brokerages recently weighed in on AEZS. ValuEngine upgraded shares of AEterna Zentaris from a “hold” rating to a “buy” rating in a report on Thursday. Zacks Investment Research upgraded shares of AEterna Zentaris from a “hold” rating to a “buy” rating and set a $1.00 target price on the stock in a report on Tuesday, October 8th. Finally, HC Wainwright restated a “buy” rating on shares of AEterna Zentaris in a report on Thursday, August 15th. Four analysts have rated the stock with a buy rating, The company has an average rating of “Buy” and a consensus price target of $2.00.
A hedge fund recently bought a new stake in AEterna Zentaris stock. Creative Planning acquired a new stake in AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 10,000 shares of the biopharmaceutical company’s stock, valued at approximately $30,000. Creative Planning owned about 0.06% of AEterna Zentaris at the end of the most recent reporting period. Institutional investors and hedge funds own 7.03% of the company’s stock.
AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last released its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported $0.01 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.14) by $0.15. AEterna Zentaris had a negative net margin of 536.79% and a negative return on equity of 1,428.66%. The firm had revenue of $0.19 million for the quarter, compared to the consensus estimate of $0.20 million. On average, analysts predict that AEterna Zentaris will post 1.77 earnings per share for the current year.
About AEterna Zentaris
Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology, endocrinology, and women's health. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications.
Featured Article: How liquidity affects the bid-ask spread
Receive News & Ratings for AEterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.